Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 10,413 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $48.91, for a total transaction of $509,299.83. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Clay B. Siegall also recently made the following trade(s):

  • On Wednesday, July 5th, Clay B. Siegall sold 10,423 shares of Seattle Genetics stock. The stock was sold at an average price of $51.98, for a total transaction of $541,787.54.
  • On Monday, June 5th, Clay B. Siegall sold 10,423 shares of Seattle Genetics stock. The stock was sold at an average price of $65.21, for a total transaction of $679,683.83.

Seattle Genetics, Inc. (SGEN) traded down 0.69% during trading on Wednesday, reaching $48.72. 763,682 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $54.31 and its 200 day moving average price is $61.56. The firm’s market cap is $6.97 billion. Seattle Genetics, Inc. has a 52-week low of $42.58 and a 52-week high of $75.36.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.03. Seattle Genetics had a negative net margin of 47.38% and a negative return on equity of 32.87%. The company had revenue of $108.20 million for the quarter, compared to the consensus estimate of $105.92 million. During the same period last year, the company posted ($0.23) EPS. The firm’s quarterly revenue was up 13.4% compared to the same quarter last year. Equities research analysts anticipate that Seattle Genetics, Inc. will post ($1.70) EPS for the current fiscal year.

WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/seattle-genetics-inc-sgen-insider-clay-b-siegall-sells-10413-shares/1466426.html.

Large investors have recently bought and sold shares of the stock. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Seattle Genetics during the first quarter worth $119,000. Tradewinds Capital Management LLC increased its stake in Seattle Genetics by 2.3% in the first quarter. Tradewinds Capital Management LLC now owns 2,344 shares of the biotechnology company’s stock worth $147,000 after buying an additional 52 shares during the last quarter. First Manhattan Co. increased its stake in Seattle Genetics by 31.3% in the second quarter. First Manhattan Co. now owns 3,150 shares of the biotechnology company’s stock worth $162,000 after buying an additional 750 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in Seattle Genetics by 562.5% in the first quarter. Daiwa Securities Group Inc. now owns 2,650 shares of the biotechnology company’s stock worth $167,000 after buying an additional 2,250 shares during the last quarter. Finally, Meeder Asset Management Inc. increased its stake in Seattle Genetics by 1,580.9% in the second quarter. Meeder Asset Management Inc. now owns 3,950 shares of the biotechnology company’s stock worth $205,000 after buying an additional 3,715 shares during the last quarter. Institutional investors own 97.91% of the company’s stock.

Several research firms have recently issued reports on SGEN. HC Wainwright boosted their price objective on shares of Seattle Genetics from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Cann restated a “hold” rating on shares of Seattle Genetics in a report on Thursday, April 27th. Zacks Investment Research upgraded shares of Seattle Genetics from a “sell” rating to a “hold” rating in a report on Tuesday, May 2nd. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Seattle Genetics in a report on Saturday, June 3rd. Finally, Cowen and Company set a $61.00 price objective on shares of Seattle Genetics and gave the stock a “hold” rating in a report on Tuesday, June 6th. Five analysts have rated the stock with a sell rating, ten have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $62.07.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.